01 — At a Glance
The Molecular Alchemist That Erased 40% of Its Quarter on Purpose
- 52-Week High / Low₹1,028 / ₹352
- FY25 Revenue (Full Year)₹1,030 Cr
- FY25 PAT (Full Year)₹305 Cr
- Full-Year FY25 EPS₹17.59
- Q3 FY26 EPS₹2.32
- Book Value₹72.4
- Price to Book4.87x
- Dividend Yield0.32%
- Debt / Equity0.02x
- 52-Week Return-57.5%
The Contradiction That Broke Your Portfolio: Blue Jet delivered FY25 PAT of ₹305 crore on ₹1,030 crore revenue (30% PAT margins). Then came Q3 FY26 — where they shipped ₹192 crore in revenue, reported ₹40 crore PAT, and somehow managed to look like they had business execution issues. The reality? Channel inventory de-stocking for their flagship Bempedoic acid intermediate + deliberate supply chain realignment. Financial engineering, not financial decline. P/E of 20.8x looks expensive until you remember FY25 EPS was ₹17.59 and annualized Q3 shows recovery coming. Stock down 57.5% in 1 year anyway. Welcome to small-cap pharma.
02 — Introduction
They Make the Stuff That Doctors Use to See Inside You. Very Unsexy. Very Profitable. Very Hated by the Market.
Blue Jet Healthcare is not the stock your friendly neighbourhood Twitter financial advisor tweets about at 2 AM while ranting about “high-growth smallcaps.” It makes contrast media intermediates. Know what those are? Neither did your portfolio manager until he realized the top 4 global contrast media manufacturers control 75% of a USD 5.9 billion market. And Blue Jet supplies intermediates to all four of them.
Incorporated in 1968. Bootstrapped. No IPO was needed — the company grew quietly for five decades, did ₹500+ crore in annual revenue by FY20, and then decided to go public in 2023. Why? Because Akshay Bansarilal Arora (founder, 62.8% stake, four decades of organic chemistry expertise) realised small-cap India had finally discovered that pharma APIs, contract manufacturing, and specialty chemicals were more defensible than “enterprise SaaS for pets” (hypothetical, but you understand).
87% export revenue. 40% ROE. 40% ROCE. ₹305 crore PAT on ₹1,030 crore sales in FY25. Dividends paid. New Vizag facility approved for ₹1,000 crore. Then Q3 happened and the stock crashed 40% in three months because management’s own inventory destocking strategy looked like demand collapse to eight analysts covering smallcap pharma at boomer brokerage houses.
This is the story of a company that’s technically executing perfectly while the market popcorns on feelings. Let’s fix that.
Concall Bomb (Feb 2026): “We are still very bullish on this product. We do not see any concern or issue.” — Management on flagship Bempedoic acid intermediate, despite Q3 looking like a bloodbath. This sentence tells you everything.
03 — Business Model: WTF Do They Even Make?
Molecular Legos for the World’s Biggest Pharma Players
Imagine you’re a global pharmaceutical innovator manufacturing a drug that lowers bad cholesterol. You need 47 chemical steps to make it work. You don’t want to build a 100,000-employee empire to make one intermediate step — you call Blue Jet. They’ve got the chemistry, the regulatory approvals, the GMP certifications, and the guts to scale production from lab batches to tonnes in six months.
Blue Jet’s three operating sites (Shahad, Ambernath, Mahad) produce three main categories: Contrast Media Intermediates (67.7% of FY24 revenue) — the chemicals that help X-rays, CT scans, and MRIs “see” inside the human body. High-Intensity Sweeteners (18.1% of revenue) — saccharin and derivatives for beverages, toothpaste, and pharma formulations. Pharma Intermediates & APIs (13.4% of revenue) — specialized molecules for cardiovascular, CNS, and oncology drug makers.
Total reaction capacity: 1,177 KL across three sites. Capacity utilization (annualized): 82% in FY24. Growth drivers include backward integration (their Mahad Unit 3 expansion into iodinated contrast media), CDMO services for late-phase molecules, and immersion cooling fluids for data centres (they joke it’s “4–5 years away, maybe sooner”).
Export Revenue87%50+ countries served
Top Customer Revenue %~63.5%Concentration Risk
ApprovalsWHO-GMP, ISO, SMETARegulatory Moat
Customer Base400+Diversified
The Hidden Moat: Global contrast media manufacturers must audit suppliers annually. Blue Jet has been validated by GE Healthcare, Guerbet, and Bracco Imaging for 4–26 years. That’s not a customer relationship — that’s regulatory imprisonment. Switching costs are astronomical.
💬 Have you ever taken a CT scan? You’ve indirectly funded Blue Jet’s R&D. Neat, right? Drop a comment if this feels like cheating the investing gods.
04 — Financials Overview
Q3 FY26: The Numbers That Made Everyone Panic
